Despite Evidence Favoring Direct Oral Anticoagulants Over Warfarin, Adoption in U.S. Clinical Practice Has Been Slow, Yale Medicine School Study Finds
December 07, 2021
December 07, 2021
NEW HAVEN, Connecticut, Dec. 7 (TNSJou) -- Yale School of Medicine issued the following news:
For decades, patients with atrial fibrillation with a moderate or severe risk for stroke were prescribed the anticoagulant warfarin. With the emergence of a safer, more effective class of oral anticoagulants, new Yale-led research examines contemporary practices among U.S. clinicians between 2013-2018.
When taken for stroke prevention, Direct-Acting Oral Anticoagulants or DOACs . . .
For decades, patients with atrial fibrillation with a moderate or severe risk for stroke were prescribed the anticoagulant warfarin. With the emergence of a safer, more effective class of oral anticoagulants, new Yale-led research examines contemporary practices among U.S. clinicians between 2013-2018.
When taken for stroke prevention, Direct-Acting Oral Anticoagulants or DOACs . . .